Who
da Silva Jorge Santos
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, MoonLake Immunotherapeutics.
In numbers
- Trades disclosed
- 31
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $24.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Oct 2023
- Last trade
- 10 Jul 2026
- Last filed
- 13 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jul 2026filed 13 Jul 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M68,289 at $20.02 | filing |
| 10 Jul 2026filed 13 Jul 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M68,289 at $20.02 | filing |
| 9 Jul 2026filed 13 Jul 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $679K33,936 at $20.01 | filing |
| 9 Jul 2026filed 13 Jul 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $679K33,936 at $20.01 | filing |
| 1 Jul 2026filed 2 Jul 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $957K47,775 at $20.03 | filing |
| 1 Jul 2026filed 2 Jul 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $957K47,775 at $20.03 | filing |
| 13 Apr 2026filed 14 Apr 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $946K51,873 at $18.23 | filing |
| 13 Apr 2026filed 14 Apr 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $946K51,873 at $18.23 | filing |
| 10 Apr 2026filed 14 Apr 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $1.8M98,127 at $18.41 | filing |
| 10 Apr 2026filed 14 Apr 2026 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $1.8M98,127 at $18.41 | filing |
| 7 Jan 2026filed 9 Jan 2026 | MLTX MoonLake Immunotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —520,342 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | MLTX MoonLake Immunotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —520,342 at $0.00 | filing |
| 19 Dec 2025filed 22 Dec 2025 | MLTX MoonLake Immunotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —5,836 | filing |
| 19 Dec 2025filed 22 Dec 2025 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Code C | —196,316 | filing |
| 19 Dec 2025filed 22 Dec 2025 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Code D | —196,316 | filing |
| 9 Dec 2025filed 10 Dec 2025 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M70,000 at $14.49 | filing |
| 8 Dec 2025filed 10 Dec 2025 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $2.0M130,000 at $15.08 | filing |
| 27 Feb 2025filed 3 Mar 2025 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Code A | —95,763 at $0.00 | filing |
| 29 Feb 2024filed 29 Feb 2024 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $265K4,740 at $55.89 | filing |
| 28 Feb 2024filed 29 Feb 2024 | MLTX MoonLake ImmunotherapeuticsBiotechnology | SEC FORM 4 Sold | $3.1M56,065 at $55.00 | filing |
News
No headline names them, or the companies they trade most, lately.